Pacira Pharmaceuticals (PCRX) PT Lowered to $82 at Needham & Company, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mail
Get Alerts PCRX Hot Sheet
Price: $36.39 --0%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 37 | New: 6
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 37 | New: 6
Join SI Premium – FREE
Needham & Company analyst Serge Belanger lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $82.00 (from $85.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Glaukos Corporation (GKOS) PT Raised to $251 at Needham
- Needham on Fiverr International Ltd. (FVRR): 'we are lowering our adj. EBITDA estimates by -63% for '27E'
- Needham Reiterates Hold Rating on ResMed (RMD)
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
